Esophageal Cancer clinical trials at UCSF
8 in progress, 4 open to eligible people
AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
open to eligible people ages 18-100
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid tumors.
San Francisco 5391959, California 5332921 and other locations
Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
open to eligible people ages 18 years and up
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
San Francisco 5391959, California 5332921 and other locations
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
open to eligible people ages 18 years and up
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.
San Francisco 5391959, California 5332921 and other locations
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
open to all eligible people
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
San Francisco 5391959, California 5332921 and other locations
(VELA) Study of BLU-222 in Advanced Solid Tumors
Sorry, in progress, not accepting new patients
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
San Francisco 5391959, California 5332921 and other locations
Beta-only IL-2 ImmunoTherapY Study
Sorry, not currently recruiting here
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
San Francisco 5391959, California 5332921 and other locations
Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Sorry, in progress, not accepting new patients
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1. This study will also assess other measures of antitumor activity; overall survival (OS); as well as the safety and tolerability of enfortumab vedotin for cohorts 1 to 8 and enfortumab vedotin + pembrolizumab in cohort 9.
San Francisco 5391959, California 5332921 and other locations
Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for Esophageal Cancer research studies include Pamela Munster Mary Feng.
Last updated: